Back

Which patients did recent trials in transthyretin amyloid cardiomyopathy select? - insights from a prospective patient registry

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Treatment of transthyretin amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Lena Marie Schmid

Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies
Doctor M. Rahman (Flushing, US)
Abstract Slides Video
Presentation thumbnail
Diagnostic, therapeutic and prognostic implications of carpal tunnel syndrome and spinal stenosis in wild-type transthyretin cardiac amyloidosis.
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis
Doctor T. Tsampras (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
Doctor F. Cappelli (Florence, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of transthyretin amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
thumbnail
Congress Presentation
Event rates in major phase 3 heart failure trials over the past 20 years
thumbnail
Congress Presentation
Conventional medical therapies in patients with heart failure across different risk for transthyretin amyloid cardiomyopathy in the DELIVER, PARAGON-HF and TOPCAT Americas trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources